Indication: Genitourinary Cancer
A Phase III, Randomized, Open Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Car
Sub-indication: Unresectable Locally Advanced or Metastatic Urothelial Cancer.
Line of Therapy: 1st Line. (Patients who have received prior definitive chemoradiation, adjuvant or neoadjuvant for locally advanced disease are eligible provided that progression to locally advanced or metastatic disease has occurred >12 months from the last therapy or >
Principal Investigator: Chandler Park, M.D.Norton Cancer Institute
Email for more information: GU-NCIResearch@nortonhealthcare.org